__NUXT_JSONP__("/drugs/Larotrectinib_Sulfate", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1223405-08-0",chebiId:b,chemicalFormula:b,definition:"The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.",fdaUniiCode:"RDF76R62ID",identifier:"C156895",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C155765"],synonyms:["(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric acid","1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, Sulfate (1:1)","ARRY 470 Sulfate","LAROTRECTINIB SULFATE","LOXO 101 Sulfate","LOXO-101 Sulfate",c,"Vitrakvi"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLarotrectinib_Sulfate",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Larotrectinib_Sulfate","","Larotrectinib Sulfate","2021-10-30T13:34:32.253Z")));